Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults

BACKGROUND: A preventative strategy for Respiratory Syncytial Virus (RSV) infection constitutes an under-recognized unmet medical need among older adults. Four formulations of a novel recombinant RSV F nanoparticle vaccine (60 or 90 μg RSV F protein, with or without aluminum phosphate adjuvant) admi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Immun Ageing
Autori principali: Fries, Louis, Shinde, Vivek, Stoddard, Jeffrey J., Thomas, D. Nigel, Kpamegan, Eloi, Lu, Hanxin, Smith, Gale, Hickman, Somia P., Piedra, Pedro, Glenn, Gregory M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2017
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5389002/
https://ncbi.nlm.nih.gov/pubmed/28413427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12979-017-0090-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi